Akihiro Sato

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Shota Fukuoka, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2020 · 926 citations · Full text

Medicine, Oncology, Pharmacology +17

Malignant Astrocytic Tumors: Clinical Importance of Apparent Diffusion Coefficient in Prediction of Grade and Prognosis

Shuichi Higano, Toshihiro Kumabe, Mika Watanabe et al. · Radiology · 2006 · 374 citations

Medicine, Oncology, Radiology +17

Non-equilibrium steady states in supramolecular polymerization

Alessandro Sorrenti, Jorge Leira-Iglesias, Akihiro Sato et al. · Nature Communications · 2017 · 333 citations · Full text

Natural Sciences, Biochemistry, Molecular Biology +17

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

Kiyotaka Yoh, Takashi Seto, Miyako Satouchi et al. · The Lancet Respiratory Medicine · 2016 · 295 citations

Medicine, Oncology, Pharmacotherapy +9

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

Akihito Kawazoe, Shota Fukuoka, Yoshiaki Nakamura et al. · The Lancet Oncology · 2020 · 270 citations

Medicine, Oncology, Pharmacology +14